Cancer and Aids: New Trends in Drug Design and Chemotherapy

Authors: Anthony Taft, Carlton; Henrique Tomich de Paula da Silva, Carlos

Source: Current Computer - Aided Drug Design, Volume 2, Number 3, September 2006 , pp. 307-324(18)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $62.88 plus tax (Refund Policy)

Abstract:

We present a comprehensive but not exhaustive review of new trends in drug discovery and targets for cancer and AIDS which begins by highlighting the different historical stages of drug discovery from clinical diagnosis, natural compounds, serendipity and chemotherapy to the present age of modern experimental and computational techniques. The current state of the art of computer-aided drug design and selected recent applications to Cancer and AIDS are discussed. Novel targets and drugs in Cancer and AIDS are analyzed. In conclusion, future perspectives for drug discovery, design and therapeutics in cancer and AIDS are presented.

Keywords: HIV-1; non-nucleoside reverse transcriptase inhibitors (N; chemokine co-receptors; anti-VEGF antibody; molecular modeling (MM)

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157340906778226382

Affiliations: 1: Centro Brasileiro de Pesquisas Fisicas, Rua Dr. Xavier Sigaud, 150, CEP, 22290-180, Rio de Janeiro, RJ, Brazil.

Publication date: 2006-09-01

More about this publication?

Current Computer-Aided Drug Design aims to publish all the latest developments in drug design based on computational techniques. The field of computer-aided drug design has had extensive impact in the area of drug design. Current Computer-Aided Drug Design is an essential journal for all medicinal chemists who wish to be kept informed and up-to-date with all the latest and important developments in computer-aided methodologies and their applications in drug discovery. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of computational techniques for drug design, screening, ADME studies, etc., providing excellent rationales for drug development.